Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.
about
A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesisTranslational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in SchizophreniaCholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activitySensory disturbances, inhibitory deficits, and the P50 wave in schizophreniaNicotinic ACh receptors as therapeutic targets in CNS disordersThe role of the habenula in drug addiction.Repurposing Drugs for Cognition in Schizophrenia.Schizophrenia.nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Negative affective states and cognitive impairments in nicotine dependenceCurrent and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.Beyond Membrane Protein Structure: Drug Discovery, Dynamics and Difficulties.Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.Nicotine receptors mediating sensorimotor gating and its enhancement by systemic nicotine.Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia.Classics in Chemical Neuroscience: Aripiprazole.AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis.Retinal ganglion cell neuroprotection induced by activation of alpha7 nicotinic acetylcholine receptors.Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands.PET imaging evaluation of [(18)F]DBT-10, a novel radioligand specific to α7 nicotinic acetylcholine receptors, in nonhuman primates.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerNeuronal Nicotinic Receptors Are Crucial for Tuning of E/I Balance in Prelimbic Cortex and for Decision-Making ProcessesLong-term effects of maternal deprivation on cholinergic system in rat brain.Neuromodulation by acetylcholine: examples from schizophrenia and depression.Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.PET tracers for imaging brain α7 nicotinic receptors: an update.Cognitive impairment in schizophrenia: the great unmet need.What is the promise of nicotinergic compounds in schizophrenia treatment?Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia.Melatonin regulates the autophagic flux via activation of alpha-7 nicotinic acetylcholine receptors.Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled TrialsAge at first tobacco use and risk of subsequent psychosis-related outcomes: A birth cohort study.Recombinant Newcastle disease virus rL-RVG enhances the apoptosis and inhibits the migration of A549 lung adenocarcinoma cells via regulating alpha 7 nicotinic acetylcholine receptors in vitroTargeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor.Retinal ganglion cell neuroprotection induced by activation of alpha7 nicotinic acetylcholine receptorsEffects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice.
P2860
Q26748778-4CE95F7A-52D2-40F4-B37C-25560C7F6524Q26801568-F474A3C1-D76B-4CD9-8C2F-53A0C82B2DE3Q26991451-96F9E066-1D0A-4415-87FD-9352E90E16DAQ27026737-1474DDF4-48FC-4DAF-BD61-B480758E21FFQ28111941-BAA5C927-E655-4A99-A4EA-C4485DDEA58DQ28238267-7B3F5604-BE39-4429-B461-45D722592718Q30244854-AB9F5CCD-D2F3-440B-9904-79D98C084EACQ30251961-FF7C3716-0200-43FA-A043-05EB0E0C3EC8Q30362464-311C0A88-CD4E-4FE3-8938-B08E9CCB7413Q30371220-DE2F86A5-76A6-4A4E-A524-9C66027D56B4Q30382281-3E0E0A06-F311-448F-B948-6BB6747E421FQ30392142-CEE7A9A8-1C8C-4587-B53F-34C856D151ABQ30396775-EDD14154-1EF0-477E-B063-043D7C5126DFQ30407039-0DA1EFED-058E-4898-B0D3-18E271673AE6Q30417995-DC454B5E-906C-4932-9C31-C33A925D5FF6Q33854995-9E6741D5-ED7D-4FBF-A553-B795405A39EFQ33866125-21D66B50-BE10-4833-A5CD-69D0B2303AA1Q35111465-B76259FE-33D0-40D7-BA6F-B678EBB6A75CQ35302795-FF49137F-14E0-4478-A07F-AD493CD8E4D1Q35736555-F03DF2B0-2ACA-4768-92B6-83F674D72FE1Q36213170-A69E9E8E-B2A6-43A4-A6F6-F046A7B1A117Q36522071-DDC94DDF-3035-4ED3-8B6E-57862B299FC6Q37258840-1905F60A-8026-466D-9885-16A007FE575CQ37339345-93271A20-BCE8-4B3A-90CF-951D40270AADQ37664402-0C1BA067-2BF7-4492-B363-255DE3463905Q38225161-3D55A268-04EE-49EB-99E6-69B0EE2DE34EQ38253573-58AF87A7-B40E-4F04-99B0-425ABD221886Q38286246-63823B66-0768-48DA-813F-75E74054A7EFQ38584762-C10FBDA8-82C2-42FB-B579-1AFE01A12F5CQ38673548-67DB2641-376C-4786-9B9C-51EE0D0E0D4EQ38811805-123A1158-7B5B-4611-8373-636C403C13D1Q38893899-E03CC978-C736-4D03-BEB4-7349B3D3A0EAQ38895371-2AE24E91-CEEF-4859-95FB-A611D3D76EE1Q41449158-0681E668-FF41-4336-A25B-979ECB51D1B5Q41687338-CA255001-07C3-4EBF-B7BF-56FB68C4EC96Q41727467-602687E9-4056-4544-BACF-39402235A990Q41925230-ACED294F-C453-4CA9-A86F-BB4E72417C77Q41977343-892EA134-04D4-4242-98B0-24C425CE501FQ41988202-E829F0BC-B55A-46A5-B349-6930D1A84740Q42365798-67217544-85FE-433C-A7ED-B64EB2B7EF91
P2860
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Evaluating the role of the alp ...... nd treatment of schizophrenia.
@ast
Evaluating the role of the alp ...... nd treatment of schizophrenia.
@en
type
label
Evaluating the role of the alp ...... nd treatment of schizophrenia.
@ast
Evaluating the role of the alp ...... nd treatment of schizophrenia.
@en
prefLabel
Evaluating the role of the alp ...... nd treatment of schizophrenia.
@ast
Evaluating the role of the alp ...... nd treatment of schizophrenia.
@en
P2860
P921
P1476
Evaluating the role of the alp ...... nd treatment of schizophrenia.
@en
P2093
Jared W Young
Mark A Geyer
P2860
P304
P356
10.1016/J.BCP.2013.06.031
P407
P577
2013-07-12T00:00:00Z